Versartis, Inc. (VSAR) Set to Announce Quarterly Earnings on Wednesday
Versartis, Inc. (NASDAQ:VSAR) will announce its earnings results after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.62) per share for the quarter.
Versartis (NASDAQ:VSAR) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.20). On average, analysts expect Versartis to post $-3.61 EPS for the current fiscal year and $-2.52 EPS for the next fiscal year.
Shares of Versartis, Inc. (NASDAQ:VSAR) opened at 2.45 on Wednesday. The stock’s market cap is $87.17 million. The stock’s 50 day moving average is $8.77 and its 200-day moving average is $15.41. Versartis, Inc. has a 12-month low of $2.35 and a 12-month high of $24.00.
A number of brokerages have recently issued reports on VSAR. Piper Jaffray Companies downgraded shares of Versartis from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $26.00 to $4.00 in a research report on Friday, September 22nd. ValuEngine downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Barclays PLC downgraded shares of Versartis from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $28.00 to $4.00 in a research report on Friday, September 22nd. Citigroup Inc. downgraded shares of Versartis from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $23.00 to $3.00 in a research report on Monday, September 25th. Finally, BidaskClub downgraded shares of Versartis from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.22.
In other Versartis news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $3.29, for a total transaction of $7,007,700.00. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders have sold 2,132,769 shares of company stock worth $7,014,761. 10.90% of the stock is owned by insiders.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.